SIXMO

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Lithuania, Poland, Romania, Spain, UK.

Active ingredients

The drug SIXMO contains one active pharmaceutical ingredient (API):

1	Buprenorphine UNII 56W8MW3EN1 - BUPRENORPHINE HYDROCHLORIDE
	Buprenorphine is an opioid partial agonist/antagonist which attaches itself to the μ (mu) and κ (kappa) receptors of the brain. Its activity in opioid maintenance treatment is attributed to its slowly reversible link with the μ receptors which, over a prolonged period, minimises the need of illicit opioids for patients with opioid dependence.
	Read more about Buprenorphine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SIXMO Implant	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N07BC01	Buprenorphine	N Nervous system → N07 Other nervous system drugs → N07B Drugs used in addictive disorders → N07BC Drugs used in opioid dependence
Discover more medicines within N07BC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1798713
ES	Centro de información online de medicamentos de la AEMPS	1191369001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	411273
FR	Base de données publique des médicaments	62898420
GB	Medicines & Healthcare Products Regulatory Agency	394938
LT	Valstybinė vaistų kontrolės tarnyba	1088111
PL	Rejestru Produktów Leczniczych	100423200
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68071001